- Home
- GALT
GALT
Galectin Therapeutics Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 256.6K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $4.27 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shlevin Harold H. | GALT | Director | Dec 30 '24 | Buy | $1.16 | 6,500 | $7,540.00 | 15,206 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership
GlobeNewswire
a month ago
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 01/17/2025
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 01/16/2025
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 01/15/2025
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 01/14/2025
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 01/13/2025
GlobeNewswire
3 months ago
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
Compare GALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.